Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rostafuroxin vs Losartan in Genetically Selected Hypertensive Patients
NCT03217825Phase 2Completed
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Dec 2015
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rostafuroxin in hypertension (HTN), sponsored by Windtree Therapeutics, Inc.. Started Dec 2015; status: completed.
02
Drugs
rostafuroxin
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03217825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217825.